Prodrugs are cunning derivatives of therapeutic agents designed to improve the
pharmacokinetics profile of the drug. Within a prodrug, pharmacological activity of the drug is …

Systemic cytotoxic (anti-proliferative) anticancer drugs rely primarily for their therapeutic
effect on cytokinetic differences between cancer and normal cells. One approach aimed at …

This review is a survey of various approaches to targeting cytotoxic anticancer drugs to
tumors primarily through biomolecules expressed by cancer cells or associated vasculature …

Antibody-directed enzyme prodrug therapy (ADEPT) is a therapeutic strategy which aims to
improve the selectivity of anticancer drugs. ADEPT is a two-step antibody targeting system …

Drug-metabolizing enzymes (DME) in tumors are capable of biotransforming a variety of
xenobiotics, including antineoplastics, resulting in either their activation or detoxification …

Glucuronides of drugs often accumulate during long term therapy. The hydrolysis of
glucuronides can be catalysed by β-glucuronidase, an enzyme expressed in many tissues …

Tumor therapy by the preferential activation of a prodrug at tumor cells targeted with an
antibody− enzyme conjugate may allow improved treatment efficacy with reduced side …

Systemic cytotoxic (antiproliferative) anticancer drugs rely primarily for their therapeutic
effect on cytokinetic differences between cancer and normal cells. One approach aimed at …

β-glucuronidase is an attractive reporter and prodrug-converting enzyme. The development
of near-IR (NIR) probes for imaging of β-glucuronidase activity would be ideal to allow …

Anticancer drugs are primarily cytotoxic agents, and exert their antitumor activity by
interfering with some aspects of DNA replication, repair, translation, or cell division. Hence …